Local and locoregional administration of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene has been demonstrated to be useful in treating established tumors in animals. Moreover, expression of the TRAIL gene from the human telomerase reverse transcriptase (hTERT) promoter can be used to prevent possible liver toxicity of the TRAIL gene. However, it remains unknown whether systemic administration of the TRAIL-expressing adenovector can be used for cancer therapy. Here, we showed that a combination of TRAIL gene therapy and gemcitabine, the first-line chemotheraphy agent for pancreatic cancer, had a synergistic effect on the induction of apoptosis in human pancreatic cancer cell lines in vitro. Systemic administration of an adenovector that contains an insertion of integrin-binding motif argine-glycine-aspartate (RGD) in the HI loop of the adenoviral fiber protein and expresses the human TRAIL gene from the hTERT promoter (designated Ad/TRAIL-F/RGD) suppressed the growth of human pancreatic tumor cells inoculated in the liver of nu/nu nude mice. Furthermore, Ad/TRAIL-F/RGD in combination with gemcitabine suppressed the tumor growth of pancreatic cancer in the liver more than did treatments consisting of each agent alone. No obvious liver toxicity was detected in any of the treatment groups. Our results suggest that TRAIL gene therapy in combination with gemcitabine might be a useful therapeutic approach for treating metastatic pancreatic cancers.
P
ancreatic cancer is the fourth leading cause of cancerrelated death in the United States.
1,2 The median survival time for patients with pancreatic cancer after diagnosis is 3-6 months, and the 5-year survival rate is less than 4% for all stages combined. 1 The poor outcome of pancreatic cancer might be caused by the fact that most patients are diagnosed at advanced stages. Only less than 20% of patients were diagnosed when the tumor was still confined to the pancreas and can be removed surgically. 3 Regrettably, treatment for patients with metastatic pancreatic cancer is less effective. Since the middle 1990s, gemcitabine, a nucleoside analogue of cytidine, has been the standard first-line therapy for patients with advanced pancreatic cancer. 3 Unfortunately, the median survival time for patients with advanced pancreatic cancer continues to be less than 6 months. 4, 5 In addition, recently published in vitro data have shown that prolonged exposure to gemcitabine led to acquired resistance in some pancreatic cancer cells. 1 There is thus a critical need for more effective therapy for pancreatic cancer. Gene therapy, which has shown promising results in animal studies, may be such a therapy. 6, 7 Indications of this come from several sources. For example, it was recently shown that pancreatic cancer cells are susceptible to TRAIL gene therapy. 8 Our studies also demonstrated that TRAIL-related hepatocyte toxicity can be prevented using the human telomerase reverse transcriptase (hTERT) promoter, which is highly active in more than 85% of human cancer cells, although inactive in most somatic cells. 9, 10 In addition, accumulating evidence has shown that the capsid proteins of adenovector, a common vector used in cancer gene therapy, can be modified to overcome vector-associated resistance. For example, modifying the adenovector by incorporating the integrin-binding motif RGD (Arg-Gly-Asp sequence) into the HI loop of the adenoviral fiber protein significantly increased transduction efficiency in cells resistant to conventional adenovectors. 11, 12 More recently, we reported that intralesional administration of an adenovector expressing the TRAIL gene from the hTERT promoter and containing an RGD modification in the fiber (designated Ad/TRAIL-F/RGD) resulted in the suppression of orthotopic pancreatic tumor growth. 13 Moreover, various preclinical and clinical studies have demonstrated that combination of gene therapy and some type of conventional anticancer therapy can improve therapeutic benefit.
14 However, it remains uknown whether TRAIL gene therapy is an effective treatment for advanced and metastatic pancreatic cancers or whether combining TRAIL gene therapy and gemcitabine will provide a benefit for the treatment of advanced and metastatic pancreatic cancers. Thus, in this study, we evaluated the combined effect of Ad/TRAIL-F/RGD and gemcitabine in vitro in two pancreatic cancer cell lines (AsPC-1 and Capan-1) and in vivo on tumor growth in the liver of a pancreatic tumor model Capan-1. Our results suggested that TRAIL gene therapy in combination with gemcitabine could be useful in the treatment of advanced and metastatic pancreatic tumors.
Material and methods

Cell lines and reagents
Two human pancreatic cell lines, AsPC-1 and Capan-1 obtained from the American Type Culture Collection (Rockville, MD), were used in this study. The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 1% glutamine, and 1% penicillin and streptomycin (Gibco-BRL, Life Technologies Inc., Grand Island, NY). All cells were cultured at 371C in a humidified incubator containing 5% CO 2 . Gemcitabine was purchased from Eli Lilly (Indianapolis, IN) and diluted to working concentrations with phosphate-buffered saline (PBS).
Adenovectors
The adenovectors used in this study have been described previously. 10, 13 Briefly, Ad/CMV-LacZ expresses lacZ gene from the early CMV promoter and Ad/TRAIL-F/ RGD expresses the human TRAIL gene from the hTERT promoter. Both are E1-deleted, replication-defective vectors with the expression cassette being inserted in the E1 region. Ad/TRAIL-F/RGD also contains an insertion of RGD sequence in the HI loop of the adenoviral fiber protein.
The expansion, purification, titration, and quality analyses of all these vectors were performed at the Keck Institutional Vector Core facility at The University of Texas MD Anderson Cancer Center as described previously. 9, 15 All viral preparations were found to be free of the E1 þ adenovirus by polymerase chain reaction assay, 9, 15 and to be free of endotoxin using an assay with a limulus amebocyte lysate endotoxins detection kit (BioWhittaker, Walkersville, MD). The titer used in this study was determined by the absorbency of the dissociated virus at A 260 nm (one A 260 nm unit ¼ 10 12 viral particles (VP)/ml); the titers determined with a plaque assay were used to obtain additive information. Particle:infectious unit ratios were usually between 30:1 and 100:1. Thus, the multiplicity of infection (MOI) of 1000 VP was equivalent to an MOI of 10-30 infectious units. Unless otherwise specified, Ad/CMV-LacZ was used as the vector control and PBS as a mock control.
Cell viability assay and synergistic analysis
Cell viability was determined using a 3-bis-(2-methoxy-4-nitro-5 sulfenyl)-(2 H)-tetrazolium-5-carboxanilide (XTT) assay (Cell Proliferation Kit II, Roche Molecular Biochemicals, Indianapolis, IN) as described previously. 9 For the determination of the cytoxicity levels of a single drug and of the combination treatments, AsPC-1 and Capan-1 cells were seeded onto 96-well plates at a density of 5 Â 10 3 cells/well. After 24 hours, the cells were treated with different MOIs (250, 500, 1000, and 2000 VP/ cell) of Ad/CMV-LacZ or Ad/TRAIL-F/RGD. Cell treated with PBS were used as mock control. Gemcitabine in varying concentrations (0.001-500 mM) was also added to each well. The cells were incubated at 371C in a humidified atmosphere containing 5% CO 2 . Cell growth and viability were quantified using an XTT assay on day 4 after treatment. The effects of the combination of Ad/TRAIL-F/RGD and gemcitabine were analyzed using CalcuSyn software (Biosoft, Cambrdige, UK) to find the combination index. Each experiment was performed in quadruplicate, and each series was repeated at least twice.
Flow cytometric assay
Fluorescence-activated cell sorting was performed as we described previously to determine apoptosis induction in vitro. 16 Briefly, cells were plated onto 100 mm plates at a density of 1 Â 10 6 cells/plate 1 day before infection by the virus. The cells were then treated with adenovectors, gemcitabine, or both at indicated doses. After incubation for 48 hours, both adherent and floating cells were harvested and washed with PBS. The cells were then fixed by 70% ethanol overnight, stained with propidium iodide (1 ml of PI, 10 ml of RNase, 9 ml of PBS, PI: 50 mg/ml) before analysis, and were used to quantify the apoptotic cells. This procedure was carried out using flow cytometry, measuring the sub-G0/G1 cellular DNA content using Cell Quest software (Becton-Dickinson, San Jose, CA, USA).
Animal studies
Animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals 10 VP/animal and intraperitoneal administration of gemcitabine at a dose of 25 mg/kg in 500 ml of PBS was started 4 days after the tumor cell inoculation and the animals were killed 28 days after the inoculation. Each animal's tumor, pancreas, liver, spleen, lung, kidneys, and brain were resected and processed for histopathological examination. Each liver was analyzed using three sections within 20 mM of each other. The visible tumor area of each slide was measured with Optimas imaging analysis software (Media Cybernatics, Silver Spring, MD). Blood was collected for measuring the serum liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) from four animals of each group before the treatments, 3 days after the last treatment, and 1 day before the animals were killed.
Statistical analysis
The drug concentrations for the combination index were calculated using CalcuSyn software (Biosoft, UK). Differences among the treatment groups were assessed using ANOVA statistical software (Statistica, Tulsa, OK). A P-value of r0.05 was considered significant.
Results
Combined effects of Ad/TRAIL-F/RGD and gemcitabine in cancer cells in vitro
We tested the combined effects of Ad/TRAIL-F/RGD and gemcitabine in two pancreatic (AsPC-1 and Capan-1) cancer cell lines. Cells were treated with an adenovector and gemcitabine at various doses. Ad/CMV-LacZ was used as the vector control. Cells treated with PBS were used as a mock control. Cell viability was determined using an XTT assay 4 days after the treatment. The result showed that at low doses of adenovectors and gemcitabine, combination of Ad/TRAIL-F/RGD plus gemcitabine has more dramatic cell killing effect than other treatment groups, including treatment with Ad/TRAIL-F/RGD or gemcitabine alone. For example, in both cell lines tested, a substantially greater reduction in cell viability was observed after the treatment of Ad/ TRAIL-F/RGD plus gemcitabine than after the other treatments when the cells were treated with adenovectors at an MOI of 250 VP/cell with or without gemcitabine at a concentration of 0.1 mM (Fig 1a) . A dramatic increase of dead cells was also observed under microscope in cells treated with Ad/TRAIL-F/RGD plus gemcitabine when compared with other treatment groups, suggesting that the combination treatment resulted in an increase in cell killings (Fig 1b) .
To further evaluate the interaction of the TRAIL gene therapy and gemcitabine therapy, we determined the combination index. The results from single agent and combination treatments showed that a strong synergistic effect occurred in the AsPC-1 and Capan-1 cells when the cells were treated with a low dose of the TRAIL-expressing vector. For example, the combination index was 0.1 when the cells were treated with 250 MOI of Ad/TRAIL-F/RGD and 1 mM gemcitabine (Fig 1c) . This synergistic effect was also observed when the cells were treated with an MOI of 500. At higher doses of the TRAIL-expressing vector and of the gemcitabine, however, only an additive or antagonistic effect was observed, presumable because at high doses, either of the single agent alone was sufficient to elicit a plateau of cell killing. Any further addition of the cytotoxic agent would not have further increased the cell killing effects.
Enhanced apoptosis induction by Ad/TRAIL-F/RGD and gemcitabine in cancer cells
We also determined apoptosis induction in the AsPC-1 and Capan-1 cells after combination therapy. For this purpose, the cells were treated with Ad/CMV-LacZ or Ad/TRAIL-F/RGD at an MOI of 500 Vp/cell, gemcitabine at a concentration of 0.1 mM, or their combinations. Apoptotic cells were quantified using a fluorescenceactivating analysis of sub-G1 at 48 hours after treatment. Compared with cells treated with PBS, Ad/CMV-LacZ, gemcitabine, or Ad/TRAIL-F/RGD alone, the combination treatment with Ad/TRAIL-F/RGD and gemcitabine dramatically increased the percentage of apoptotic cells (Fig 2) . Together, these results suggested that the combination of Ad/TRAIL-F/RGD and gemcitabine has an enhanced effect in apoptosis induction in pancreatic cancer cells.
Suppression of pancreatic tumor growth in the liver
To test whether the effect observed in vitro in cultured cells could also be obtained in vivo in established tumors, we inoculated Capan-1 cells into the livers of 6-week-old nu/nu nude mice. At 4 days after the tumor cell inoculation, the mice were randomly assigned to one of four treatment groups (gemcitabine, Ad/TRAIL-F/RGD, Ad/CMV-LacZ þ gemcitabine, or Ad/TRAIL-F/RGD þ gemcitabine) as described in the Materials and methods. The treatments were repeated every 2 days for a total of three treatments per animal. The animals were killed 28 days after the cell inoculation, and the tumor areas were measured. Each animal's liver and other organs were collected and sectioned for histopathological studies. Tumors in the liver were measured by quantifying tumor areas of three sections per tumor using Optimas imaging analysis software. All animals except two of the five mice treated with the Ad/TRAIL-F/RGD plus gemcitabine developed a tumor growth in the liver lobe (Fig 3a) . These two were tumor free in the liver. In all animals analyzed, none had a tumor that had grown in other organs or other liver lobes or had peritoneal carcinomatosis when they were killed. There was no significant difference in tumor sizes among animals treated with Ad/CMV-LacZ, gemcitabine, or Ad/CMVLacZ þ gemcitabine. Compared with the Ad/CMV-LacZ or Ad/CMV-LacZ þ gemcitabine treatment, Ad/TRAIL-F/RGD plus gemcitabine significantly suppressed tumor growth (Po.05). The mean tumor area in the animals treated with Ad/TRAIL-F/RGD was six times less than Suppressing tumor growth in liver by TRAIL gene D Jacob et al that in the animals treated with Ad/CMV-LacZ þ gemcitabine (Fig 3b) . Moreover, the combination of Ad/TRAIL-F/RGD plus gemcitabine dramatically decreased tumor size more than either of the two treatments alone did (Fig 3) .
Minimal toxicity of Ad/TRAIL-F/RGD plus gemcitabine or gemcitabine alone
To determine possible liver toxicity after the systemic administration of Ad/TRAIL-F/RGD and the intraper- itoneal injection of gemcitabine, we evaluated the liver enzymes AST and ALT before treatment, 3 days after the last treatment, and 1 day before the animals were killed. The results of the serum liver enzyme assays of the animals treated with Ad/CMV-LacZ, Ad/TRAIL-F/ RGD, gemcitabine, ad/TRAIL-F/RGD plus gemcitabine were all within normal ranges at all the times tested (data not shown). Furthermore, no animals died during the treatment, suggesting that the treatment was well tolerated.
Discussion
The liver is one of the most common sites of metastasis from a variety of tumors, second only to the lymph nodes. 17, 18 Unfortunately, only less than 10% of patients with liver metastasis are potential candidates for curative resection. 17, 18 Moreover, the presence of disseminated tumor cells undetectable using current diagnostic methods frequently leads to tumor relapse after complete resection. [19] [20] [21] Thus, strategies for treating liver metastasis are highly desirable. Here, we used pancreatic cancer cells growing in the liver as a model for treating liver metastasis because treatment options for patients with advanced pancreatic cancer are particularly limited.
Our in vitro and in vivo studies showed that TRAIL gene therapy plus gemcitabine enhanced cell killing in pancreatic cells. A synergistic effect of the combination of the TRAIL protein and with various types of chemotherapy has also been reported for various other cancer cells, including breast, 22, 23 ovary, 24 mesothelioma, 25 and pancreas. 26, 27 The mechanism of the synergy may be related to the upregulation of death receptor DR4, or DR5, or both, [28] [29] [30] but the results of studies on the correlation of cell receptor expression and cell death after TRAIL administration are still controversial. 25, 27 It has also been reported that simultaneous treatment of pancreatic cancer cells with TRAIL and gemcitabine leads to increased caspase-3 and caspase-8 activities, 27 suggesting that apoptosis induction was enhanced by this combination. Our data on apoptosis induced by TRAIL gene therapy plus gemcitabine support these previous reports. Together, these results provided useful preclinical evidence for future design of multimodality clinical trials consisting TRAIL gene therapy and gemcitabine chemotherapy.
Systemic administration of gene therapy would be necessary for the treatment of liver metastasis. However, the efficiency with which adenovirus tumor cells in the liver after systemic injection is substantially lower than the efficiency of direct intratumoral injection. 31 For this reason, in this study we began treating the liver tumors relatively early. Our results showed that treatment with Ad/TRAIL-F/RGD plus gemcitabine substantially suppressed the growth of pancreatic tumors in liver when the Ad/TRAIL-F/RGD was delivered systemically via the tail vein during an early treatment. It will be interesting to test whether systemic administration of the TRAIL gene in combination with gemcitabine will also be effective against larger liver tumors. Studies of cancer cell lines resistant to conventional therapy may also extend our knowledge of effective means of treating liver metastasis.
It is noteworthy that the presence of neutralizing antibody in blood may negate the effect of adenovectors administered systemically. However, promising technology for protecting adenoviral vectors from neutralizing antibodies has recently been reported by several groups. For example, the modification of adenovectors with polyethylene glycol, 32, 33 formulating adenovector in a collagen-based matrix, 34 and encapsulating adenovector in bilamellar cationic liposome 35 have all been reported to 
